A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2016
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 17 Apr 2016 Pharmacokinetics and safety results (n = 20) presented at The International Liver Congress™ 2016.
- 26 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.